1. a) Eren ZS, Tunçer S, Gezer G, Yildirim LT, Banerjee S, Yilmaz A. Improved solubility of celecoxib by inclusion in SBA-15 mesoporous silica: Drug loading in different solvents and release. Microporous and Mesoporous Materials. 2016;235:211 – 23; b) Vallet-Regí M, Schüth F, Lozano D, Colilla M, Manzano M, Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?, Chem. Soc. Rev., 2022, 51, 5365–5451; c) Iranshahy M, Hanafi-Bojd MY, Aghili SH, Iranshahi M, Nabavi SM, Saberi S, Filosa R, Farzam Nezhad I, Hasanpour M, Curcumin-loaded mesoporous silica nanoparticles for drug delivery: synthesis, biological assays and therapeutic potential – a review, RSC Adv., 2023, 13, 22250–22267; d) Lohiya G, Katti DS, Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy, Carbohydrate Polymers,2022, 277, 118822
2. Vavsari VF, Ziarani GM, Badiei A. The role of SBA-15 in drug delivery. RSC advances. 2015;5(111):91686–707.
3. Albayati TM, Salih IK, Alazzawi HF. Synthesis and characterization of a modified surface of SBA-15 mesoporous silica for a chloramphenicol drug delivery system. Heliyon. 2019;5(10):e02539.
4. Goscianska J, Olejnik A, Nowak I. APTES-functionalized mesoporous silica as a vehicle for antipyrine–adsorption and release studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2017;533:187–96.
5. Ganguly R, Kumar S, Tripathi A, Basu M, Verma G, Sarma HD, Chaudhari DP, Aswal VK, Melo JS. Structural and therapeutic properties of Pluronic® P123/F127 micellar systems and their modulation by salt and essential oil. Journal of Molecular Liquids. 2020;310:113231.